TY - JOUR
T1 - Quantification of endocannabinoids in rat biological samples by GC/MS
T2 - Technical and theoretical considerations
AU - Hardison, Sarah
AU - Weintraub, Susan T.
AU - Giuffrida, Andrea
N1 - Funding Information:
This work was supported by National Institute of Health NS 050401-02 (AG).
PY - 2006/12
Y1 - 2006/12
N2 - In the last several years, interest has increased significantly about the endocannabinoids anandamide and 2-arachidonylglycerol, two lipid messengers that activate cannabinoid receptors. Quantification of these compounds in biological samples presents numerous technical challenges. Because of their low abundance, endocannabinoids are usually quantified by isotope dilution assays using mass spectrometry coupled to either gas chromatography or high-performance liquid chromatography. Although endocannabinoid levels in biological fluids, such as plasma and cerebrospinal fluid, can be directly determined by these techniques, the complex lipid profile of brain tissue samples mandates purification of lipid extracts before GC/MS analysis; this step is not necessary when using HPLC/MS. We have found that when silica gel chromatography is used for endocannabinoid purification, poor recovery and loss of deuterium from the internal standards lead to inaccurate estimation of endocannabinoid levels. By contrast, purification strategies using C18 solid-phase extraction permits precise and reproducible GC/MS quantification of endocannabinoids in tissue samples.
AB - In the last several years, interest has increased significantly about the endocannabinoids anandamide and 2-arachidonylglycerol, two lipid messengers that activate cannabinoid receptors. Quantification of these compounds in biological samples presents numerous technical challenges. Because of their low abundance, endocannabinoids are usually quantified by isotope dilution assays using mass spectrometry coupled to either gas chromatography or high-performance liquid chromatography. Although endocannabinoid levels in biological fluids, such as plasma and cerebrospinal fluid, can be directly determined by these techniques, the complex lipid profile of brain tissue samples mandates purification of lipid extracts before GC/MS analysis; this step is not necessary when using HPLC/MS. We have found that when silica gel chromatography is used for endocannabinoid purification, poor recovery and loss of deuterium from the internal standards lead to inaccurate estimation of endocannabinoid levels. By contrast, purification strategies using C18 solid-phase extraction permits precise and reproducible GC/MS quantification of endocannabinoids in tissue samples.
KW - 2-Arachidonylglycerol
KW - Anandamide
KW - Gas chromatography
KW - Lipids
KW - Mass spectrometry
KW - Solid-phase extraction
UR - http://www.scopus.com/inward/record.url?scp=33750495827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750495827&partnerID=8YFLogxK
U2 - 10.1016/j.prostaglandins.2006.08.002
DO - 10.1016/j.prostaglandins.2006.08.002
M3 - Article
C2 - 17085319
AN - SCOPUS:33750495827
SN - 1098-8823
VL - 81
SP - 106
EP - 112
JO - Prostaglandins and Other Lipid Mediators
JF - Prostaglandins and Other Lipid Mediators
IS - 3-4
ER -